CA HPV 20-50%
HPV DNA DNA
HPV HPV- - HPV-
Koutsky s 1% 14% 60% 25% ( ) HPV Koutsky, L. 1997
( )
HPV
HPV : 75% 1% 15% HPV 1% HIV
HPV T CD3 + TCD4 + T H CD8 + T S CD4 + / CD8 + T CD69 + IL-2 Th1 HLA-DR CD38
HPV NK NKIFN- NK Th1/Th2Th2 IFN- IL-2 T IL-12 IL-18 NK IL-10 T NK CTL Th2
HPV CXC CC C CX3C DC NK
,,
CA IFN-alpha IFN Beta CDC 2003 3
IRM
Toll (TLR) 10 (TLR 1-10) 3M IRMs TLR7 TLR8
1980 3M : 1997 11FDA 2004 5, B-US04052603 2010 2 25, 4,689,338( )
1997 11 ( ) CDC STD CA* STD CA STD CA CDC STD CA * CA Condyloma Acuminatum
Dr. John F. Gerster Dr. Richard L. Miller 2004
/ IFN INF : & LCs () T HPV,
CK HPV 1 -INF HPV HPV T 2 HPV T 3 THPV 5 T 4
TOLL
3 6-10 16 20% CO 2
100 80 60 40 20 0 77 56 40 28 14 6 P<.0001 P<.0001 P<.0001 5% Edwards et al, Arch Dermatol, 1998
100 90 80 70 >50% 60 50 40 30 20 10 0 91 81 74 45 31 23 5% Edwards et al, Arch Dermatol, 1998
70 67 60 50 40 30 20 10 0 24 32 8 24 2 16 1 15 2 5% Edwards et al, Arch Dermatol 1998
13% Wart-free patients Patients with recurrence 87% N=45 13 12 Edwards L, et al. Arch Dermatol 1998.
: 5 6 : 4
Male patient: pre study Male patient: After 16 weeks of imiquimod 5% therapy
Edwards 311 5%109 54 50% 12 13% 1% 102 21 21% 100 11 11% 12 10%
Gruber Gruber
258 129 6 850% 60.66% 74 1 4 5.41%. 2003;36:501-504.
2006 2445% 125 2 4 6 852% 74.4% 81.6% 92.8% 5-Fu 119 2 4 6 852.1% 70.59% 78.15% 89.92% 5%. 2006;32:3-5.
Raymond Maw 1986 International Journal of STD & AIDS Volume 15 June 2004
% % 5% 0.15% 0.5% 33 72 37 91 9 19 4 91 (20 25%) 5- - - - A - TA-GW ( HPV6 L2E7 ) 27 88 61 94 23 52 23 72 35 72 47 13 43 3 63 17 67 6 90 40 13 21 22 60 77 23 65 19 29 63 11 50 19 54 9 69 6 10
% % 5% 33 72 9 19 21 22 60 77 23 65 19 29 63 - - - 3 63 17 67 6 90 19 54 9 69 6
! Bowen s
Korman 3,12-16 24.7% Schulze 3-7,1-2 /,6-12 75% Shumack 3-7,1-2 /, 12-16 72-76% Schacker Recurrent Genital 1-2,16 3.1-4.9% Herpes Syed 3,12-16 82%, Bowen,,,
2~5 4~12 1~5% B